President Trump wants to “make America slim again,” said Kara Kennedy in The Free Press. Standing beside drug execs in the Oval Office earlier this month, Trump announced deals with Eli Lilly and Novo Nordisk that will cut the price of their GLP-1 weight loss medicines, Zepbound and Wegovy, in return for a three-year exemption from his 100% pharmaceutical tariffs. Medicare recipients will pay a $50 monthly co-pay for the drugs, which will also be available on TrumpRx.gov—a government-run site—for $350 a month. That’s a steep discount on current list prices, which top $1,000, and will expand access to the “single most effective intervention we have against obesity,” a disease that kills up to 500,000 Americans and costs the U.S. health care system some $173 billion every year. With Trump, “

See Full Page